TY - JOUR
T1 - Production and transplantation of bioengineered lung into a large-animal model
AU - Nichols, Joan E.
AU - La Francesca, Saverio
AU - Niles, Jean A.
AU - Vega, Stephanie P.
AU - Argueta, Lissenya B.
AU - Frank, Luba
AU - Christiani, David C.
AU - Pyles, Richard B.
AU - Himes, Blanca E.
AU - Zhang, Ruyang
AU - Li, Su
AU - Sakamoto, Jason
AU - Rhudy, Jessica
AU - Hendricks, Greg
AU - Begarani, Filippo
AU - Liu, Xuewu
AU - Patrikeev, Igor
AU - Pal, Rahul
AU - Usheva, Emiliya
AU - Vargas, Grace
AU - Miller, Aaron
AU - Woodson, Lee
AU - Wacher, Adam
AU - Grimaldo, Maria
AU - Weaver, Daniil
AU - Mlcak, Ron
AU - Cortiella, Joaquin
N1 - Publisher Copyright:
Copyright © 2018 The Authors, some rights reserved;.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - The inability to produce perfusable microvasculature networks capable of supporting tissue survival and of withstanding physiological pressures without leakage is a fundamental problem facing the field of tissue engineering. Microvasculature is critically important for production of bioengineered lung (BEL), which requires systemic circulation to support tissue survival and coordination of circulatory and respiratory systems to ensure proper gas exchange. To advance our understanding of vascularization after bioengineered organ transplantation, we produced and transplanted BEL without creation of a pulmonary artery anastomosis in a porcine model. A single pneumonectomy, performed 1 month before BEL implantation, provided the source of autologous cells used to bioengineer the organ on an acellular lung scaffold. During 30 days of bioreactor culture, we facilitated systemic vessel development using growth factor-loaded microparticles. We evaluated recipient survival, autograft (BEL) vascular and parenchymal tissue development, graft rejection, and microbiome reestablishment in autografted animals 10 hours, 2 weeks, 1 month, and 2 months after transplant. BEL became well vascularized as early as 2 weeks after transplant, and formation of alveolar tissue was observed in all animals (n = 4). There was no indication of transplant rejection. BEL continued to develop after transplant and did not require addition of exogenous growth factors to drive cell proliferation or lung and vascular tissue development. The sterile BEL was seeded and colonized by the bacterial community of the native lung.
AB - The inability to produce perfusable microvasculature networks capable of supporting tissue survival and of withstanding physiological pressures without leakage is a fundamental problem facing the field of tissue engineering. Microvasculature is critically important for production of bioengineered lung (BEL), which requires systemic circulation to support tissue survival and coordination of circulatory and respiratory systems to ensure proper gas exchange. To advance our understanding of vascularization after bioengineered organ transplantation, we produced and transplanted BEL without creation of a pulmonary artery anastomosis in a porcine model. A single pneumonectomy, performed 1 month before BEL implantation, provided the source of autologous cells used to bioengineer the organ on an acellular lung scaffold. During 30 days of bioreactor culture, we facilitated systemic vessel development using growth factor-loaded microparticles. We evaluated recipient survival, autograft (BEL) vascular and parenchymal tissue development, graft rejection, and microbiome reestablishment in autografted animals 10 hours, 2 weeks, 1 month, and 2 months after transplant. BEL became well vascularized as early as 2 weeks after transplant, and formation of alveolar tissue was observed in all animals (n = 4). There was no indication of transplant rejection. BEL continued to develop after transplant and did not require addition of exogenous growth factors to drive cell proliferation or lung and vascular tissue development. The sterile BEL was seeded and colonized by the bacterial community of the native lung.
UR - http://www.scopus.com/inward/record.url?scp=85050961040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050961040&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aao3926
DO - 10.1126/scitranslmed.aao3926
M3 - Article
C2 - 30068570
AN - SCOPUS:85050961040
SN - 1946-6234
VL - 10
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 452
M1 - eaao3926
ER -